Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Charles River Laboratories Intl. Inc (CRL) vs Kinross Gold Corporation (KGC) Price & Performance

Charles River Laboratories Intl. IncTrade
Kinross Gold CorporationTrade

Price performance (Past 24H)

Key statistics

Charles River Laboratories Intl. Inc vs Kinross Gold Corporation — how do they compare? Charles River Laboratories Intl. Inc trades at $287.43 (market cap $13.46B), while Kinross Gold Corporation trades at $27.24 (market cap $32.29B). The key difference: Kinross Gold Corporation is far larger — about 2.4× Charles River Laboratories Intl. Inc's market cap, and Kinross Gold Corporation pays a 0.59% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.

CRLKGC
Market Cap
$13.46B$32.29B
Sector
HealthBasic Materials
52-Week High
$284.37$38.06
52-Week Low
$145.57$18.70
Enterprise Value
$16.30B$30.37B
Dividend Yield
0.59%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.

The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.

Kinross Gold Corporation

Kinross Gold (KGC) trades at $27.70, up 1.09% today, with a bullish technical signal from moving averages but overbought RSI levels. The company demonstrates robust fundamentals, with Q2 2026 EPS beating estimates at $0.71 versus $0.66 expected, and strong cash flow growth, with 2025 operating cash flow at $3.76 billion. Recent news includes a credit rating upgrade to 'BBB' by S&P Global Ratings on August 6, 2026, and ongoing project developments like Lobo-Marte.

The outlook is positive, supported by earnings beats, rising gold prices, and a consensus price target of $37.20, implying 34% upside. Risks include cost pressures and gold price volatility, but institutional buying and a 58.6% analyst buy rating suggest confidence in continued growth.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL

About Kinross Gold Corporation

Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.

Read more on KGC